# Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma

> **NCT07274787** · NA · NOT_YET_RECRUITING · sponsor: **University of Cincinnati** · enrollment: 10 (estimated)

## Conditions studied

- GBM

## Interventions

- **DEVICE:** NaviFUS System
- **DRUG:** Lumason
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT07274787
- **Lead sponsor:** University of Cincinnati
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2028-06-01
- **Final completion:** 2029-06-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07274787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07274787, "Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07274787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*